Uveitis Treatment Market
Uveitis Treatment Market - By Disease Type, â€‹â€‹â€‹â€‹â€‹â€‹â€‹By Cause,By Treatment Type, By Distribution Channel & Global Region - Market Size, Share, Trends and Forecast 2020-2025Request Sample Request Discount
Uveitis, an autoimmune eye disease is the internal inflammation of the uvea or the uveal tract, the layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea comprises of the ciliary body, iris, and choroid.
Uveitis is caused due to infection with a virus, fungus, bacteria, parasite, injuries and other inflammatory disease. Usual symptoms related to uveitis which directly affects the eye include eye pain, eye floaters, blurred vision, increased sensitivity to light and redness of the eye. It can lead to poor vision or complete blindness both to humans as well as animals. Therefore, it is an ophthalmic emergency and requires urgent treatment to control the inflammation.
Corticosteroid is typically deemed to be the first-line therapy for the treatment of uveitis. Also, immunosuppressant, monoclonal antibodies, cycloplegic agents, antibiotics, antivirals, antifungal, and analgesics along with various other drug formulations are used for the treatment of uveitis.
The global uveitis treatment market is expected to grow at a CAGR of around 4-7% over the period of next 5 years.
The growth of this market is attributed towards major pertaining factors including; the rising prevalence of uveitis and related complications worldwide, the high occurrence of autoimmune disorders globally, the upsurge in the development of biological drugs for the treatment of uveitis, the spurring demand for advanced healthcare products, the rising number of government initiatives to minimize eye disorders coupled with the presence of grants and fellowships, the growing popularity of advanced therapeutics, and the robust development of healthcare infrastructure in various developing nations etc.
Additionally, the ophthalmological sector has been witnessing enormous traction in the research and development activities recently for new drug discovery also leading to development of ideal therapeutics. Increasing amount of investments for R&D activities is giving rise to more and more clinical studies being performed for treating eye inflammation globally. A lot of new stage III clinical trials for refractory post or intermediate uveitis are currently under development. This is creating ample opportunities for the growth of the uveitis treatment market.
Moreover, the affluent market players present in the market are seen to be emphasizing on making technological advancements and introducing new and innovative products into the market rapidly. As a result, novel drug formulations which can reduce uveitis and allow ophthalmologist to offer improved ophthalmic treatment and patient care are being extensively developed. This also leads to improved efficiency and safety profiles in the clinical trial stage of development, thereby reducing the progression of disease considerably. For instance, players in uveitis treatment are focusing on introducing steroid implants, which is proving out to be rigorously accepted for drug delivery in case of noninfectious posterior uveitis and also adjuvant immunosuppressing agents which have proven to be efficient in the recent past.
Furthermore, other factors such as the growing geriatric populace, the fast-track approval of pipeline drugs, the increasing disposable incomes of people coupled with high expenditure on healthcare and the increasing number of clinical trials for eye inflammation treatment are further enhancing the growth of the market.. Also, the increasing numbers of hospitals, diagnostic centers, online treatments is also contributing massively in fueling the growth of the uveitis treatment market.
However, factors such as the adverse effects related to uveitis treatment medication such as watery eyes etc., the high cost associated with treatment, the poor primary healthcare infrastructure, the absence of awareness about eye disorders, the unavailability of health insurance in developing countries, lack of skilled professionals and the unknown etiology and pathophysiology of uveitis, hinder the growth of this market.
UVEITIS TREATMENT MARKET SEGMENTATION:
By Disease Type:
- Intermediate Uveitis
- Posterior Uveitis
- Anterior Uveitis
By Treatment Type:
- Monoclonal Antibodies
- Cycloplegic Agents
By Distribution Channel:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
The North American region is the most prominent and the largest regional market for uveitis treatment followed by Europe. The region is anticipated to maintain its position at the top in the upcoming years also on account of various factors such as; the increasing incidence of infectious uveitis and related disorders in the region, the early approval of pipeline drugs as compared to other regions in the region, the advanced healthcare infrastructure in the region, the increasing investments in research and development by drug manufacturing companies for innovating new treatments such as corticosteroids, the high patient awareness levels about eye disorders and the favorable refund policies available in the region etc. The major contributors in the region include the U.S and Canada.
The European region is the second largest market for uveitis treatment and the same is anticipated to witness substantial growth in the forthcoming years. The growth in the region can be attributed to factors such as the growing prevalence of autoimmune disorders such as AIDS and multiple sclerosis in the region, the growing R&D initiatives and activities in the region, the rising incidence of eye diseases in the region, the active conducting of clinical trials in the region as well as rising healthcare expenditure in this region etc. The major contributors in the region are Germany, France and the U.K.
The Asia Pacific region is the third largest and the fastest growing regional market for uveitis treatment. The region is set to continue to experience growth at a substantial rate in the upcoming years owing to factors such as the growing prevalence of patients affected with uveitis in the region, the absence of sanitation of infectious illnesses in the developing countries in the region, the increasing awareness regarding different therapy options available in the region and the rising government initiatives to curtail eye disorders in the region. Additionally, the increasing aging population, the growing disposable incomes of people in the region and the developing medical infrastructure in the region also contribute significantly in the growth of this uveitis treatment regional market. The major contributors in the region include India, Japan and China. Countries such as Singapore and South Korea are also looking to gain momentum and are contributing to the growth significantly since the past years.
FEW KEY PLAYERS IN UVEITIS TREATMENT MARKET:
- Bausch & Lomb Incorporated
- Novartis AG
- Eyegate Pharmaceuticals Inc.
- Alimera Sciences Inc
- Amgen Inc.
- Clearside Biomedical Inc.
- EyePoint Pharmaceuticals Inc.
- Mylan N.V.
- Ophthalix Inc.
- Santen Pharmaceutical Co. Ltd.
- Topivert Ltd.
- Regeneron Pharmaceuticals Inc.
- pSivida Corp.
- Allergan India Private Limited
- Enzo Biochem Inc.
- AbbVie Inc.
- Other Players
- In December 2020, Akari Therapeutics, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated announced the publication of the results of a two-year research collaboration with the University College of London (UCL) Institute of Ophthalmology. The results showed that the therapeutic intravitreal (IVT) administration of long-acting nomacopan mitigated the severity and progress of retinal damage in two models of autoimmune uveitis, a severe inflammatory eye disease where steroids are the primary treatment option. In addition, results showed the presence of inflammatory cells expressing both complement C5 and LTB4 receptors in retinal tissue from donor patients with uveitis as compared to healthy donor eyes.
- In February 2021, Alimera Sciences, Inc., a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announced that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime.
Custom Research Requirement? Questions to ask?Get in touch
Custom Research requirement.